DAVID BRUNEL, CHAIRMAN OF THE BOARD OF DIRECTORS
Mr. Brunel has been involved in enterprise software for over 25 years and has been involved in molecular diagnostics since 2000. Mr. Brunel was a founder and CEO of Unidata, Inc. when it merged with Vmark Software to create Ardent Software, Inc., where he was President and COO. He was also a member of the Board of Ardent until it was sold to Informix in 1999. Mr. Brunel was also a co-founder and President of SomaLogic, Inc., a company focused on creating protein capture arrays for sensitive, high-throughput, quantitative diagnostics. Mr. Brunel is also on the board of Anark Corporation and Xyleme, Inc.
GREG ABBOTT, JD. BOARD OF DIRECTORS MEMBER
Mr. Abbott has over 30 years of experience serving as Director, Chief Executive Officer and company officer of numerous biotech companies including Synergen and Darwin Molecular. He has also worked as a corporate and finance attorney and been a partner with the Silicon Valley law firm of Cooley LLP, for which he co-founded and managed a branch office in Kirkland, Washington. Previously, as a partner with Holme Roberts & Owen in Colorado, he led the firm’s technology practice and co-founded a branch office in Boulder, Colorado. Mr. Abbott has worked for many years as a biotech industry consultant, company advisor, and expert witness in biotech and technology licensing litigation. Today he is an Emeritus Attorney in the State of Washington, where he has volunteered on numerous cases for Northwest Immigrant Rights Project and served on its Board of Directors. He has also volunteered as an advisor to college-bound, low income, first generation students for College Access Now, and served on that organization’s Board of Directors. Mr. Abbott holds a B.A. from Yale, a J.D. with honors from the University of Denver Sturm College of Law, and has been a Fulbright Scholar in law in Moscow, Russia.
DAVID L. BARKER, PHD. BOARD OF DIRECTORS MEMBER
Dr. David L. Barker currently serves on the Boards of Directors of AmideBio, Singular Genomics Systems, and Aspen Neuroscience, and is Board Member and Chairman at Bionano Genomics (NASDAC: BNGO). He is a scientific advisor to MiNDERA Corp. and Luna DNA. He was Vice President and Chief Scientific Officer at Illumina, Inc., from 2000 to 2007, and on the Illumina scientific advisory board through 2015. He was previously on the Boards of NextBio, which was acquired by Illumina in 2013, ProteinSimple, which was acquired by Bio-Techne in 2014, Zephyrus Biosciences, Inc., acquired by Bio-Techne in 2016, IntegenX, acquired by Thermo Fisher Scientific in 2018, and Integrated Diagnostics, acquired by Biodesix in 2018. Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham.
In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.
PAWEL FLUDZINSKI, PHD, BOARD OF DIRECTORS MEMBER, PRESIDENT AND CEO
Dr Fludzinski became CEO of AmideBio in May, 2018. Prior to AmideBio, he had a 31 year career with Eli Lilly and Company, with 23 years in executive leadership positions in the United States, United Kingdom, and Japan, encompassing roles in strategy, research and drug development. In addition, he was one of the founding members of Lilly BioVentures. In his final role at Lilly, he served as Global Brand Development Leader within the Diabetes Business Unit at Lilly where he led a cross functional team though Phase 2, Phase 3 clinical development and global registration of TRULICITY®, Lilly’s once-a week agent for glycemic control in type 2 diabetes. He holds a Ph.D. in organic chemistry from the University of Rochester, Rochester NY, and was a National Institutes of Health Postdoctoral Fellow at Columbia University, New York City, NY.
VINCE P. MIHALIK, MS. BOARD OF DIRECTORS MEMBER
Mr. Mihalik has a combined 40 years of experience in the pharmaceutical and biomedical industries. He most recently served as the Senior Vice President, Sales and Marketing, and Chief Commercial Officer of Amylin Pharmaceuticals. Prior to joining Amylin, he was Vice President Global Brand Development and Commercialization for the Diabetes and Endocrine Platform at Eli Lilly. From 1998 to 2001, he served as Senior Vice President and General Manager for Lab Systems and Molecular Biochemicals at Roche Diagnostics. From 1990 to 1998, he served in various management capacities at Boehringer Mannheim including, President Diabetes Care North America. Prior to this he held various positions of increasing responsibility at American Hospital Supply Corporation (AHSC) and Baxter Healthcare, after the latter acquired AHSC in 1985. His final roles being that of President and General Manager of the Pandex R&D division of Baxter. He holds a B.S. degree in Biology from Pennsylvania State University and a Masters in Management from Northwestern University.
MIKHAIL “MISHA” PLAM, PHD, EMERITUS CHAIRMAN OF THE BOARD OF DIRECTORS AND CO-FOUNDER
Dr. Plam is cofounder of AmideBio, LLC. Prior to AmideBio Dr. Plam was Founder, President and CEO of BiOptix, commercial provider of a novel Surface Plasmon Resonance-enhanced Common Path Interferometer system platform used for the detection of molecular interactions. In 1994 Dr. Plam founded and served as Chairman, President and CEO of Sievers Instruments, an analytical instrument company acquired by General Electric (NYSE: GE). In 1997, Dr. Plam was selected as the Ernst & Young Entrepreneur-of-the-Year (Rocky Mountain Region), was named Entrepreneur of Distinction at Esprit ’97 Boulder (Colorado) and in 2010 he received University of Colorado Serial Startup Entrepreneur Award. In 2011, Dr. Plam received SBA/Tibbets award for propagation of SBIR program in several countries and successful commercialization of technologies. Dr. Plam is a member the Advisory Board at The University of Colorado Center for Entrepreneurship.
MICHAEL H. B. STOWELL, PHD. BOARD OF DIRECTORS MEMBER, CO-FOUNDER AND CTO
Dr. Stowell is an Associate Professor of Molecular Biology and Mechanical Engineering at the University of Colorado, Boulder and has authored a wide range of publications in the fields of synthetic organic chemistry, structural biology, neurobiology, and biophysics. Dr. Stowell has received numerous grants and awards including the Beckman Young Investigator Award, a National Institutes of Health – EUREKA award, and a Howard Hughes Medical Institute – Collaborative Innovation Award. Dr. Stowell received his Ph.D. in Chemistry and Biophysics from the California Institute of Technology and was a visiting Scientist at the MRC – Laboratory of Molecular Biology, Cambridge England and the Biophysics Department of Kyoto University, Japan.
NILES F. UTLAUT, MD. BOARD OF DIRECTORS MEMBER
Dr. Utlaut has been practicing medicine for over 33 years. He is Board Certified in Internal Medicine and Ophthalmology, studied at the National Eye Institute, was a researcher at Moorfields Hospital, London, served on the faculty at Stanford University and, acted as Attending Physician to the Royal Family of Saudi Arabia. Dr. Utlaut held prior posts as President of the Colorado Business Coalition for Health, Director of the Royal Hospital at Taif, Saudi Arabia; and, on the Board of Directors for Magpie Healthcare and Avivid Business Solutions. Dr. Utlaut was Valedictorian in Mathematics at the University of Colorado, and holds a M.D. from Johns Hopkins School of Medicine.